MDL 17,043: Short- and long-term cardiopulmonary and clinical effects in patients with heart failure

This publication has 10 references indexed in Scilit:

• Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement.
  Circulation, 1985
• Comparative hemodynamic effects of intravenous dobutamine and MDL-17,043, a new cardioactive drug, in severe congestive heart failure
  American Heart Journal, 1985
• Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic severe heart failure
  American Heart Journal, 1984
• Intravenous and oral MDL 17043 (A new inotrope-vasodilator agent) in congestive heart failure: Hemodynamic and clinical evaluation in 38 patients
  Journal of the American College of Cardiology, 1984
• Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failure
  Journal of the American College of Cardiology, 1984
• Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance
  The American Journal of Cardiology, 1984
• The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure.
  Circulation, 1983
• Accuracy of cardiac output, oxygen uptake and arteriovenous oxygen difference at rest, during exercise and after vasodilator therapy in patients with severe, chronic heart failure
  The American Journal of Cardiology, 1982
• Arterial oxygenation and arterial oxygen transport in chronic myocardial failure at rest, during exercise and after hydralazine treatment.
  Circulation, 1982
• Metabolic assessment of exercise in chronic heart failure patients treated with short-term vasodilators.
  Circulation, 1980